Credits: Canva/PA wire
They’ve survived the unthinkable—only to be left behind. Tens of thousands of people across the UK were infected with HIV, hepatitis B, or hepatitis C after receiving contaminated blood products through the National Health Service (NHS) between the 1970s and early 1990s. Over 3,000 have died. Those who remain—living with irreversible health damage—say they are “waiting to die in limbo,” abandoned by a system that once harmed them and is now delaying their compensation.
The scandal is now one of the gravest failures in the history of public health and medical ethics in Britain. Yet even after a damning public inquiry and the announcement of a compensation package exceeding £11.8 billion, the process of justice remains painfully slow and exclusionary.
Also Read: FDA Approves New Covid Vaccine For Kids With Selective Eligibility
The infected blood scandal didn’t happen in a vacuum. Throughout the 1970s and 80s, the UK faced a growing demand for clotting agents like Factor VIII, used to treat patients with conditions such as haemophilia. But with domestic supply falling short, the NHS began importing blood plasma—mainly from the United States.
Much of that plasma came from high-risk groups, including prisoners and intravenous drug users, who were often paid to donate. These donations were frequently contaminated with hepatitis viruses and HIV.
Shockingly, UK authorities continued using these high-risk blood products for years, even after risks were known. Blood donations were not routinely screened for hepatitis C until 1991—18 months after the virus had already been identified.
Over 30,000 NHS patients were exposed. Many were children. Some were subjected to medical trials without consent. The result? A generation of individuals living with chronic illnesses and systemic health complications that never should have happened.
HIV, hepatitis B, and hepatitis C are life-altering conditions. Beyond the immediate risk of organ damage, liver failure, or immunosuppression, the emotional toll is immense. Survivors often live with persistent fatigue, neurological symptoms, chronic pain, and mental health challenges, including PTSD and anxiety. Stigma around HIV and hepatitis has also caused widespread social isolation.
Women infected through childbirth or transfusions during pregnancy face added burdens. Children of infected parents have lost caregivers. Many victims stayed silent for decades, fearing shame or professional consequences.
In 2017, the UK government finally launched a statutory inquiry into the scandal. The final report, released in May 2024, called out a pervasive cover-up by the NHS and government. The evidence was clear: thousands were knowingly exposed to risk. The response was too little, too late.
Also Read: South Asia Continues To Remain The 'Global Epicentre' Of Anemia Among Girls
Following the report, a multi-billion-pound compensation fund was announced but fast forward to mid-2025, and only 460 victims have received full compensation out of more than 2,000 invited to submit claims. Tens of thousands more are still waiting—even to be allowed to apply.
Sir Brian Langstaff, chair of the public inquiry and British judge, was blunt in a supplemental 200-page report released in July 2025. “People are being harmed further,” he said. “Obvious injustices” include:
Rather than being centered around the people it aims to serve, the scheme was built behind closed doors—mirroring the secrecy that caused the original disaster.
Here's what many don’t grasp: delayed compensation isn’t just a bureaucratic failure—it’s a health crisis.
Many victims are now elderly or seriously ill. Without financial support, they face barriers to adequate care, end-of-life support, and medical treatments not covered by the NHS. Mental health, too, has deteriorated among survivors, many of whom feel abandoned yet again.
The current criteria for proving psychological harm require evidence from a consultant psychiatrist with long-term treatment records. But in the 1980s and 90s, such services were rarely available, especially outside major cities. For many victims, disclosing their status even to medical professionals meant risking stigma, job loss, or personal rejection.
Requiring documentation they could never have safely obtained isn’t just unfair, it’s cruel.
To understand the scale of this injustice, it’s crucial to look at what infections like HIV and hepatitis do to the body:
HIV (Human Immunodeficiency Virus) attacks the immune system, making the body vulnerable to other infections and certain cancers. Without treatment, it progresses to AIDS. Even with antiretroviral therapy, it can cause long-term fatigue, cognitive issues, cardiovascular problems, and reduced life expectancy.
Hepatitis B and C target the liver. Chronic infection can lead to cirrhosis, liver failure, and hepatocellular carcinoma. Many infected individuals require lifelong antiviral medication and liver monitoring.
These viruses are spread through contact with infected blood, sexual fluids, or contaminated medical tools. Even a single exposure can lead to lifelong health consequences.
Despite allocating £11.8 billion, the UK government has been slow to implement recommendations. Sir Brian’s report calls for:
The Infected Blood Compensation Authority has so far processed a fraction of the claims. Survivors continue to ask: if the government has known this was coming for years, why are we still waiting?
While this scandal is rooted in the UK, the message applies globally- trust in healthcare systems is fragile. Once broken, it’s hard to rebuild.
Scandals like this shake confidence in public health not just in transfusions, but in vaccines, medications, and institutional care. When victims are sidelined, when compensation is delayed, and when transparency is lacking, the public loses faith.
Credits: AP
Becky Quick recently spoke about her 9-year-old daughter Kaylie’s private struggle with a rare genetic disorder. In an interview with People, published Thursday, January 8, the 53-year-old co-anchor of CNBC’s Squawk Box revealed that Kaylie has SYNGAP1. According to the Child Neurology Foundation, SYNGAP1 is a genetic condition that can cause seizures and developmental challenges. Quick recalled that she first noticed something was off “probably around 8 months,” when Kaylie wasn’t reaching her developmental milestones.
“Sometimes her eyes would cross. You just know as a mom that something isn’t right,” Quick told People, adding that after observing her daughter and reviewing developmental studies, it became clear that Kaylie wasn’t meeting expected benchmarks. “We immediately began working with therapists. They supported Kaylie in rolling over, achieving fluid movements, eventually walking, and so many other skills. But we also noticed additional concerns developing.”
For nearly a decade, Quick has kept her daughter Kaylie’s SYNGAP1 diagnosis private. The condition, as defined by the Children’s Hospital of Philadelphia, is a rare genetic disorder that can lead to a variety of neurodevelopmental challenges. It currently has no cure and often requires round-the-clock care.
The journalist took Kaylie to her pediatrician, who recommended a study with a developmental specialist. The results confirmed Quick’s fears: her daughter was not reaching key milestones.
“We started working with therapists immediately,” Quick said. “[They] helped Kaylie develop rolling, fluid movement, eventually walking, and many other skills. But we also observed additional issues.”
A neurologist then performed an EEG study, which revealed that Kaylie was experiencing subclinical seizures — subtle seizures that aren’t visibly noticeable. A subsequent genetic test confirmed that Kaylie had SYNGAP1.
SYNGAP1 (SRD) refers both to a gene and the rare neurological disorder it causes. The condition is marked by intellectual disability, epilepsy, and autism spectrum traits, arising from a mutation that reduces the SynGAP protein, which is essential for proper synaptic function in the brain, according to MedlinePlus. Without adequate SYNGAP1 protein, synapses become overly excitable, impairing communication between neurons and leading to the neurological difficulties observed in SYNGAP1 patients, as per National Institute of Health.
SYNGAP1 is considered a spectrum disorder, meaning patients experience symptoms differently and with varying severity. The exact factors influencing symptom expression or intensity remain unclear. The most commonly observed signs include, as per NIH:
SYNGAP1-related disorders arise from a variant on the SYNGAP1 gene (6p.21.32). Each human cell contains 23 pairs of chromosomes, totaling 46, with thousands of genes on each chromosome. Most genes come in pairs, one inherited from each parent, and their primary role is to produce proteins that regulate tissues and organs.
When a gene experiences a variant, sometimes called a mutation or alteration — it can stop functioning properly. Variants occur naturally, similar to a typo when DNA is copied from cell to cell, or they may result from environmental factors.
A de novo variant is a genetic change that appears for the first time in a family, occurring early in reproductive development. Most SYNGAP1 patients carry de novo variants. For families with a genetic report, understanding the variant can help clarify the diagnosis and guide next steps.
Credits: iStock
Indians are popping antacids like candies, and they are putting their hearts, kidneys and gut health at risk. Doctors from time and again have cautioned patients to not take such pills without prescriptions.
Antacids are prescribed proton pump inhibitors or PPIs, used commonly to reduce the amount of acid in the stomach and helps to treat and prevent various acid related conditions. However, in India, acidity is not treat as a symptom, but a lifestyle condition, which has made these pills so common. These over the counter access also created medical complacency, this means the availability has blurred the line between short term relief and long term therapy.
Repeated use is increasingly associated with acute interstitial nephritis and chronic kidney disease. What makes this dangerous is that kidney damage often develops silently, discovered only when kidney function has already deteriorated significantly.
It also impact the gut microbiome, and causes chronic digestive problems. Stomach acid regulates gut bacteria. Suppressing it allows harmful bacteria to flourish, leading to bloating, infections, diarrhea, and conditions like small intestinal bacterial overgrowth (SIBO).
Furthermore, regular usage of antacids could make your bones weak too. As per a 2023 study published in the journal BioMed Research International, pantoprazole cause bone loss, which could be prevented by adding octreotide.
The study analyzed the serum levels of calcium, phosphorus, and ALP before starting the treatment, and at the end of 12 weeks of treatment on pantoprazole, significant decline in calcium levels were noticed, as compared with other groups. The study also found that octreotide significantly prevented the effect of pantoprazole on the serum levels of calcium and ALP.
The study also found that pantoprazole decreased femoral bone density and femoral BMAD. Besides this, another decrease was found in the femoral bone weight and volume as well as the trabecular volume.
Frequent heartburn is also a symptom of gastroesophageal reflux disease or GERD. This is a condition in which the valve between the stomach and the lower esophagus malfunctions and allows stomach acid to bubble up into the esophagus. This is often treated with antacid, which may mask the real problem.
Over time, untreated GERD can injure the lining of the esophagus and increase the risk of serious complications, including Barrett’s esophagus, a condition that can raise cancer risk. Also, symptoms often blamed on heartburn, such as chest pain or burning, can sometimes signal a heart attack. That’s why experts stress getting a proper medical evaluation before self-treating with antacids.
Famotidine (Pepcid, Calmicid, Fluxid, Mylanta AR) is a potent H2 blocker used to manage acidity and heartburn. Studies show that famotidine is not thought to raise the risk of osteoporosis.
Other options: Ranitidine (Zantac - where available, as it was withdrawn in some markets due to safety concerns) and Nizatidine are other H2 blockers.
Note: Health & Me do not encourage discontinuance of any prescribed medicine by a doctor. Before making any change in your medicine schedule, please speak to your doctor/GP.
Credits: iStock
Nasal spray warnings are given by doctors and experts as the long use of it could lead to worsening of condition. The Royal Pharmaceutical Society (RPS) advised the public to not use nasal decongestant for more than seven days, as it contains xylometazoline or oxymetazoline. Its prolonged use can cause 'rebound congestion' or increased dependency on these sprays to breathe easily.
A recent poll, reports the Independent found out that almost six in 10 pharmacists report patients were unaware of the dangers of its extended use. Due to the increased number of flu activity, symptoms like blocked nose has increased, which has lead to a high usage of nasal spray.
It is a preventable condition, and is scientifically known as rhinitis medicamentosa, which causes the symptoms to worsen. Patients become depended on the sprays to breathe more easily.
RPS survey of 300 pharmacists found that 59% think the public is not aware of the risks, while 75% said packaging should be clearer about the seven-day limit. 63% said they had intervened in cases of suspected overuse.
Professor Amira Guirguis, chief scientist at RPS told the ITV News, "Nasal decongestant sprays can be helpful for short-term relief, but using them for longer than seven days can make your congestion significantly worse. Our research shows that many people are unaware of this risk, which means they may continue using these sprays without realizing they could be prolonging their symptoms. We'd like to see clearer warnings on the packaging which you can't miss and greater awareness of the seven-day limit. If your congestion lasts more than a week, speak to your pharmacist. There are safe and effective alternative options to help you manage your symptoms."
Another survey by ITV News suggests that more than a fifth of adults have used the products for longer than seven days. This means 5.5 million people in the UK may have risked developing a dependency.
Read: Bristol Hospitals Under Severe Strain as Flu and Cold Weather Hit the Region
As ITV News reported, Charlotte Johnstone, who is 30, had been using nasal spray multiple times a day since she was seven years old. She realized that the impact of this so-called addiction has caused her anxiety and left her "dreaming about not being able to breathe". She told ITV News, “I can’t sleep without having it, I wake up and the first thing I do is have my nasal spray. I don’t like eating if I’ve got a blocked up nose, it just makes me feel claustrophobic. I wouldn’t put myself in a situation where I don’t have it. “I go through stages of losing my sense of smell. I know it’s doing something but I don’t know what. But for the sake of having a clear nose, I’ll just take it,” she said.
A spokesperson from PAGB, the consumer healthcare association representing the manufacturers of these products, said: “The patient information leaflet which accompanies all nasal decongestant sprays, includes these instructions and outlines the risks of taking the medication for longer than its indicated use. As explained on the information supplied with the nasal decongestant sprays, OTC medicines manufacturers provide comprehensive accessible information to support people to make responsible informed decisions about the right product to self-care for their self-treatable condition," reported ITV News.
© 2024 Bennett, Coleman & Company Limited